| Subject: | FDA Public Health Notification: Potentially Fatal Errors with GDH-PQQ Glucose Monitoring Technology |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Fri, 14 Aug 2009 - 06:00 am |
| The FDA notified healthcare professionals of the possibility of falsely elevated blood glucose results when using GDH-PQQ glucose test strips on patients who are receiving therapeutic products containing certain non-glucose sugars. GDH-PQQ glucose monitoring measures a patient's blood glucose value using methodology that cannot distinguish between glucose and other sugars. Certain non-glucose sugars, including maltose, xylose, and galactose, are found in certain drug and biologic... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
